In the circumstances, these are sensible decisions.
I agree with you about Lumos 'gambling' on an outcome.
It was somewhat fortuitous that the company received the news from the FDA after their recent capital raise. It may have otherwise been lights out for Lumos.
The new CEO now has an opportunity to fix some of the past mistakes, and so far he's making the right moves.
Fortunately, Lumos is not a one trick pony. The science, diagnostic tests and IP looks good. They have bought themselves some time to secure regulatory approval for their other diagnostic tests, while getting this review or new submission for FebriDx right.
With cash in the bank and an EV close to zero, this is worth backing IMO.
In the circumstances, these are sensible decisions. I agree with...
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.005(13.5%) |
Mkt cap ! $17.80M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 4.5¢ | 3.9¢ | $477.7K | 11.25M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 423 | 4.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.3¢ | 258645 | 2 |
View Market Depth
| Last trade - 10.16am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
3.9¢ |
Change
0.005 ( 11.4 %) |
||||
| Open | High | Low | Volume | ||
| 4.0¢ | 4.5¢ | 3.9¢ | 7162434 | ||
| Last updated 10.34am 04/06/2024 ? | |||||
| LDX (ASX) Chart |